Pearl River Capital’s Ginkgo Bioworks DNA Stock Holding History

Pearl River Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,767	Closed	-$168K	–	479
2022 Q2	$168K	Buy	+1,767	New	+$216K	0.04%	418

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pearl River Capital's DNA Position: Q3 2022 in Review

Pearl River Capital sold out of Ginkgo Bioworks (DNA) in Q3 2022, closing a stake of 1,767 shares — an estimated $168K sold.

Pearl River Capital first reported a position in DNA in Q2 2022 and held it in 1 quarter. The position peaked at $168K in Q2 2022. 278 funds tracked by Wall St. Rank hold DNA as of Q3 2022.

Pearl River Capital reported no remaining Ginkgo Bioworks position as of Q3 2022 after selling out during the quarter.
Pearl River Capital sold 1,767 Ginkgo Bioworks shares in Q3 2022, an estimated $168K.
Pearl River Capital first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 1 quarter.
Pearl River Capital's Ginkgo Bioworks position peaked at $168K in Q2 2022.
278 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2022.

Based on Pearl River Capital's 13F filing for Q3 2022, filed 14 Nov 2022.